Tolerance induction to prevent allograft rejection is a long-standing clinical goal.
| INTRODUCTION
The goal of transplant tolerance is to achieve long-term allograft survival without ongoing immunosuppression. Preclinical studies in the cynomolgus nonhuman primate (NHP) 1 using bone marrow transplantation (BMT) to induce mixed chimerism has led to promising phase 1 trials. 2 The immunologic mechanisms leading to peripheral tolerance are complex and likely involve, in part, regulatory T cells 3, 4 and regulatory B cells. 5 Reliable identification of tolerance could benefit clinical trials and provide insights into the immunologic mechanisms.
RNA expression is frequently used in transplantation to identify important inflammatory patterns and potential biomarkers of rejection. [6] [7] [8] [9] [10] [11] [12] [13] Although exciting, not all investigations identify similar patterns of RNA expression. 6, 11, [14] [15] [16] [17] [18] Studies of tolerance are more limited. Transcripts in blood lymphocytes in spontaneously tolerant recipients suggest involvement of a B cell signature. 19, 20 In liver allografts, tolerance is associated with an altered expression of iron metabolism genes. 21 To our knowledge, an intragraft tolerance gene signature in renal allografts has not been reported, although elevated FOXP3:GZMB ratios were reported in biopsy specimens from a mixed chimerism protocol. 
O R I G I N A L A R T I C L E

RNA expression profiling of nonhuman primate renal allograft rejection identifies tolerance
The nCounter Analysis System (NanoString Technologies, Seattle, WA) is a novel RNA expression platform both highly multiplexed and flexible and works reliably with formalin-fixed paraffin-embedded (FFPE) tissue. 23 We previously validated the use of this system in renal allograft rejection in an NHP, the cynomolgus monkey, and demonstrated that RNA expression correlates well with expected rejection patterns and Banff criteria. 24 This mixed chimerism protocol in cynomolgus monkeys [25] [26] [27] [28] [29] with no immunosuppression 1 month postinduction engenders long-term kidney allograft survival leading to either tolerance or eventual rejection. These animals have protocol or indication kidney specimens, for which significant archival FFPE tissue is available.
The goal of the current study is to use such archival renal allograft specimens to identify patterns of intragraft RNA gene expression that are associated with rejection, long-term allograft survival, or tolerance.
| METHODS
| Animals
Each of 76 animals underwent 1 of the 2 study protocols: either standard protocol in which induction medications were used with BMT at day 0 or a delayed protocol in which induction medications were de- 
| Specimens and Pathology
Data are from 76 animals, which underwent 1 to 11 biopsies from 0 to 5983 days posttransplantation (N = 278), including protocol (45.8%) or for-cause (31.6%) biopsies, plus autopsy nephrectomies (22.6%).
Of the animals that underwent BMT, 21.4% lacked a terminal rejec- 
| Pathology
Specimens (N = 278) were scored and interpreted by using the Banff criteria, 30 including diagnostic grades of rejection and Banff ordinal criteria scores (0-3), plus nominal (positive or negative) donor-specific antibody (DSA) and C4d. 27 Rejection grades were computed in the 
| Gene set
The gene set includes 67 oliognucleotides, previously described probes, 31 
| Alloantibodies
Alloantibodies were identified by indirect flow cytometry on donor T and B cells and scored as nominal data as either positive or negative. 28 Class I or class II alloantibodies were not distinguished. Figure 1 shows the probability of survival with 95% confidence Table 1 shows the positive statistically significant scaled RNA expression F I G U R E 1 Life distribution plot of renal allografts among cynomolgus monkeys with BMT without rejection, with BMT and terminal rejection, and control without BMT. Life distribution with compare groups using terminal time, y time to event, and groups with the 3 groups. Log normal distribution and IFN inducible genes that is an expected pattern for TCMR 16 and is called the TCMR factor. In factor 3, endothelial genes show dominant expressions, the expected pattern found in CAMR, 39 and this factor is called the CAMR factor.
| Data and statistical analyses
| RESULTS
Next, to validate these 3 factors, we identified their significant SEs within the 5 diagnostic categories defined in Methods. example, the gene expressions from the same animal in a sample from 100 days posttransplantation may or may not be biologically relevant to the gene expressions in a sample from 1000 days posttransplantation. To address this problem, additional analyses were compared both per sample and per animal.
To test the relevance of these 3 factors to allograft survival, a probability formula was calculated both per sample and per animal by using logistic regression with terminal rejection as the binary dependent variable versus the 3 factors as the independent variables. Plots of these data ( Figure 3) show that for both the per-animal ( Figure 3A) and the per-sample calculations ( Figure 3B ), the Tolerance factor positively correlates with probability of no terminal rejection, whereas the TCMR and CAMR factors inversely correlate with the probability of no terminal rejection (ie, actual terminal rejection). The FDRPV for the probabilities in Figure 3A are Tolerance factor, 5.0 × 10 . The FDRPV for the probabilities in Figure 3B are Tolerant factor, 1.0 × 10
; TCMR factor, 2.0 × 10
; and CAMR factor, 2.5 × 10
Additional evidence supporting the relationship of these 3 factors to long-term allograft survival is shown in Figure 4 , in which a To test if these 3 factors derive meaningful biological groups, K-means clustering partitioned these 3 factors into 9 clusters-8 clusters plus the normal group. and Quiescent (no pathologic rejection). But some groups are additional and are not identified within standard pathologic diagnoses due to the presence of the latent variable, the Tolerance factor. The most interesting group is the Tolerant cluster identified exclusively by its statistically significant and dominant Tolerance factor. Table S4 shows the days posttransplantation and creatinine levels for all samples in the 8 non-normal clusters and the terminal days and terminal creatinine for the animals in the 8 non-normal clusters.
To determine if the factor-clustered groups are biologically relevant and differentially correlate with allograft survivals, 2 tests were performed. Figure 1 shows that BMT prolongs terminal rejection but not indefinitely because about 78% of the animals have terminal rejections. The prior probability of rejection or prevalence of rejection in this BMT model data set is, therefore, known. Given the prior probability, a Bayes calculation of the posterior probability of rejection was calculated for the 8 non-normal clusters, both per sample and per animal. Table 3 shows a Bayes table of posterior probabilities for terminal rejection with the clusters both per specimen and per animal.
All clusters except the Tolerant cluster show posterior probabilities of terminal rejection that were higher than 63% or higher than the prior probability. The Tolerant group has a posterior probability of 39% per sample or 22% per animal, both much lower than the prior probability.
The Tolerant cluster is, therefore, deemed more likely tolerant and less likely to have a terminal rejection.
To test if these factor cluster groups differentially partition allograft survivals, Life distribution and Cox proportional hazard calculations were performed. Figure 6A ) and per animal ( Figure 6B ). Data in Figure 6 show that within the Tolerant cluster, many more samples or animals have a higher probability of tolerance. Overall, the data in relevant with the longest allograft survival, the lowest probability of terminal rejection, and the lowest relative risk of terminal rejection.
This model was tested by cross-validation using logistic regression for terminal rejection using the 3 factors with random validation (Figure 7 ). The area under the receiver operating characteristic curve (AUC) is 80% or greater with a misclassification rate of 15.5%.
Investigators using RNA expression try to reduce the number of informative genes to a smaller number, which might have predictive
Comparison program to compare the probability of no terminal rejection for the 3 factors, individual factors, and the 15 highest genes in the Tolerance factor ( Table 1 ). The probability calculation includes random validation. Table 4 shows the AUC for the 3 factors, individual factors, and the 15 highest genes in the Tolerance factors. The AUC is highest, 0.82, for the 3 factors. Also, included in Table 4 If a clustered group contains a significantly elevated TCMR and/or CAMR factor in addition to the Tolerance factor, allograft survival is most likely shortened ( 
DISCLOSURE
